HC Wainwright Issues Optimistic Forecast for AMLX Earnings

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Equities researchers at HC Wainwright upped their Q2 2026 earnings per share estimates for shares of Amylyx Pharmaceuticals in a research note issued to investors on Friday, May 8th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.33) per share for the quarter, up from their previous estimate of ($0.34). HC Wainwright has a “Buy” rating and a $34.00 price objective on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.28) EPS, FY2028 earnings at ($0.96) EPS, FY2029 earnings at $1.79 EPS and FY2030 earnings at $3.87 EPS.

A number of other equities research analysts have also recently issued reports on the company. Bank of America upped their price objective on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Stifel Nicolaus began coverage on Amylyx Pharmaceuticals in a research note on Tuesday, March 3rd. They set a “buy” rating and a $21.00 price objective on the stock. Wall Street Zen cut Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Friday. Finally, Mizuho upped their price objective on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Amylyx Pharmaceuticals Stock Down 3.0%

Shares of Amylyx Pharmaceuticals stock opened at $14.44 on Wednesday. Amylyx Pharmaceuticals has a 12-month low of $4.20 and a 12-month high of $18.60. The stock has a market cap of $1.61 billion, a P/E ratio of -9.63 and a beta of -0.11. The business’s 50 day moving average is $15.34 and its 200-day moving average is $14.25.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMLX. Meeder Asset Management Inc. acquired a new position in Amylyx Pharmaceuticals in the 4th quarter valued at $25,000. KBC Group NV acquired a new position in Amylyx Pharmaceuticals in the 1st quarter valued at $26,000. California State Teachers Retirement System acquired a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at $28,000. Caitong International Asset Management Co. Ltd grew its holdings in Amylyx Pharmaceuticals by 954.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock valued at $47,000 after buying an additional 3,493 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after buying an additional 5,904 shares in the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.